お知らせ
Date |
Announcement |
|---|---|
| September 16, 2021 |
Repligen Announces Agreement to Acquire Avitide Inc. Read More |
| September 9, 2021 |
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies |
|
September 3, 2021 |
Repligen Extends Long Term Supply Agreement with Cytiva for Affinity Ligands. Read More |
|
2021年6月22日 |
Repligen Corporation Announces Agreement to Acquire Polymem S.A. Read More |
|
February 8, 2021 |
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More |
|
October 27, 2020 |
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More |
| October 1, 2020 |
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More |
|
2020年6月29日 |
Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More |
|
April 26, 2019 |
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies. Read More |
|
Septermber 4, 2018 |
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More |
|
2018年6月28日 |
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand. Read More |
|
2018年6月27日 |
Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands. Read More |
|
2017年6月23日 |
Repligen Corporation and Spectrum Inc. to Join Forces. Read More |
|
December 15, 2016 |
Repligen acquires TangenX Technology Corporation. Read More |
|
October 4, 2016 |
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification. Read More |
|
April 4, 2016 |
Repligen acquires Atoll GmbH. Read More |
最近のニュース
Press Contact
Sondra Newman
Senior Director, Investor Relations
Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115